Goldman Sachs’s Aktis Oncology AKTS Stock Holding History

Goldman Sachs’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$686K	Sell	21,278 -8,885	-29%	-$182K	﹤0.01%	5490
2026 Q1	$540K	Buy	+30,163	New	+$586K	﹤0.01%	5556

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs's AKTS Position: Q2 2026 in Review

Goldman Sachs reduced its Aktis Oncology (AKTS) stake by 29% in Q2 2026, selling an estimated $182K and leaving 21,278 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #5490.

Goldman Sachs first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

Goldman Sachs held 21,278 shares of Aktis Oncology worth $686K as of Q2 2026.
Goldman Sachs sold 8,885 Aktis Oncology shares in Q2 2026, an estimated $182K.
Aktis Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5490 holding.
Goldman Sachs first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.